{"type":"trials","record":{"id":41909,"source_id":"clinicaltrials-gov","external_id":"NCT04264819","title":"Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration","brief_summary":"Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid exudation, and fibrosis, resulting in photoreceptor damage and vision loss.","overall_status":"Completed","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Novartis Pharmaceuticals","enrollment":295,"countries":["France"],"start_date":"2020-12-14","completion_date":"2023-05-10","last_update_date":"2024-11-07","source_url":"https://clinicaltrials.gov/study/NCT04264819","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"SWIFT","age_range":"50 Years","comparator":null,"organization":"Novartis","interventions":["RTH258/Brolucizumab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of Patients With no Disease Activity at Week 16 in the Study Eye — Week 16","Number of Patients With no Disease Activity at Week 48 in the Study Eye — Week 48","Change From Baseline in CFST (Central Sub-Field Retinal Thickness) as Assessed by OCT (Optical Coherence Tomography) Ov…","Absence of IRF (Intraretinal Fluid), SRF (Subretinal Fluid), and Sub-RPE (Retinal Pigmented Epithelium) Fluid as Assess…","Number of Patients With a Dry Retina (Neither IRF Nor SRF) up to Week 48 in the Study Eye — Baseline, Weeks 4, 8, 16, 48","Distribution of the Last Interval With no Disease Activity up to Week 48 in the Study Eye — Intervals of 0,4,5,6,7,8,9,…","Distribution of the Maximal Intervals With no Disease Activity up to Week 48 in the Study Eye — Intervals of 0,4,5,6,7,…","Average Change in BCVA (Best-Corrected Visual Acuity) From Baseline up to Week 48 in the Study Eye — Baseline, Weeks 4,…","Summary of Treatment-emergent Adverse Events - Overall — Adverse events were reported from first dose of study treatmen…","Summary of Treatment-emergent Adverse Events Regardless of Study Treatment Relationship by Primary System Organ Class,…"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":true},"controlled_terms":["Neovascular Age-Related Macular Degeneration","RTH258/Brolucizumab"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04264819","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2020-12-14 to 2023-05-10","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.890Z","intervention":["RTH258/Brolucizumab"],"participants":295,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of Patients With no Disease Activity at Week 16 in the Study Eye — Week 16","Number of Patients With no Disease Activity at Week 48 in the Study Eye — Week 48","Change From Baseline in CFST (Central Sub-Field Retinal Thickness) as Assessed by OCT (Optical Coherence Tomography) Ov…","Absence of IRF (Intraretinal Fluid), SRF (Subretinal Fluid), and Sub-RPE (Retinal Pigmented Epithelium) Fluid as Assess…","Number of Patients With a Dry Retina (Neither IRF Nor SRF) up to Week 48 in the Study Eye — Baseline, Weeks 4, 8, 16, 48","Distribution of the Last Interval With no Disease Activity up to Week 48 in the Study Eye — Intervals of 0,4,5,6,7,8,9,…","Distribution of the Maximal Intervals With no Disease Activity up to Week 48 in the Study Eye — Intervals of 0,4,5,6,7,…","Average Change in BCVA (Best-Corrected Visual Acuity) From Baseline up to Week 48 in the Study Eye — Baseline, Weeks 4,…","Summary of Treatment-emergent Adverse Events - Overall — Adverse events were reported from first dose of study treatmen…","Summary of Treatment-emergent Adverse Events Regardless of Study Treatment Relationship by Primary System Organ Class,…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41909","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}